Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

It is intended for both secondary prevention in individuals with biomarker-positive disease and primary preventive therapy for individuals at elevated risk of Alzheimer’s pathology due to known ...

It is intended for both secondary prevention in individuals with biomarker-positive disease and primary preventive therapy for individuals at elevated risk of Alzheimer's pathology due to known ...

Alzheimer’s disease is a neurological disorder marked by memory loss, diminished cognitive function, and difficulties with day-to-day activities. As the world’s population ages, Alzheimer’s disease ...